CJC-1295 and Ipamorelin: Why the Pair Is Studied Together

For laboratory research use only.

CJC-1295 and ipamorelin are frequently discussed together because they act on two different receptors that both influence pituitary growth-hormone output. CJC-1295 is a growth hormone–releasing hormone (GHRH) analog; ipamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor GHS-R1a. Understanding that split is more useful than treating the pair as one interchangeable reagent.

CJC-1295: a long-acting GHRH(1–29) design

In the foundational chemistry and pharmacology paper, CJC-1295 was identified as a tetrasubstituted form of human GRF(1–29) carrying a C-terminal maleimidopropionamide “drug affinity complex” (DAC) intended to covalently bind serum albumin and extend circulating half-life (Jette et al., 2005). In rat studies summarized there, the construct remained detectable for days and increased GH exposure relative to unmodified GRF(1–29).

Healthy-adult trials of the long-acting analog reported sustained elevations of GH and IGF-I after subcutaneous administration, with an estimated half-life on the order of several days (Teichman et al., 2006). A related overnight sampling study found that GH pulsatility was preserved while trough GH and IGF-I rose after a single dose (Ionescu & Frohman, 2006). Those datasets describe the DAC-bearing molecule studied in the clinic; retail shorthand that labels short-acting modified GRF 1–29 as “CJC-1295 without DAC” should not inherit that pharmacokinetic evidence without confirmation of the actual construct.

Ipamorelin: a selective GHS-R1a pentapeptide

Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2. Raun and colleagues characterized it as a potent GHRP-receptor agonist that released GH from rat pituitary cells and in vivo with efficacy similar to GHRP-6, while showing markedly less ACTH/cortisol stimulation than GHRP-6 or GHRP-2 in swine even at high multiples of the GH ED50 (Raun et al., 1998). That selectivity profile is why it is often chosen when investigators want a GHS-R1a ligand with a narrower endocrine footprint than earlier hexapeptides.

Why the two pathways are combined in research discussions

GHRH-receptor signaling and ghrelin-receptor signaling are separate inputs into somatotrophs. Older work combining GHRH with GHRPs showed that the pathways can interact; that history motivates pairing a GHRH analog with a selective GHS ligand. Importantly, controlled trials that administer modern CJC-1295 together with ipamorelin as a fixed combination are not the same evidence base as the component studies above. Catalog co-listing therefore reflects receptor logic more than a completed combination dossier.

Practical distinctions

  • CJC-1295 (DAC literature) ≠ modified GRF 1–29 / “no DAC” unless sequence and reactive group match the studied construct.
  • Ipamorelin ≠ GHRP-2 or GHRP-6, despite shared GHS-R1a class membership.
  • GHRH analogs ≠ GHRPs; different receptors, different primary papers.

Neither compound’s research literature converts a laboratory listing into established clinical benefit for unsupervised use. Read primary papers for the exact chemotype your protocol names.

Sources

Shopping Cart
Scroll to Top